Introduction {#s1}
============

The neuromuscular junction (NMJ) is a tripartite synapse comprised of an α-motor neuron (the presynapse), extrafusal muscle fiber (the postsynapse), and specialized synaptic glia called perisynaptic Schwann cells (PSCs) or terminal Schwann cells. Due to its large size and accessibility, extensive research of the NMJ has been essential to the discovery of the fundamental mechanisms that govern synaptic function, including the concepts of neurotransmitter release, quantal transmission, and active zones, among others ([@bib41]; [@bib23]; [@bib83]; [@bib87]; [@bib86]; [@bib81]; [@bib18]; [@bib40]; [@bib76]; [@bib12]; [@bib28]; [@bib38]; [@bib49]; [@bib58]; [@bib68]). Likewise, the concept of glia that exist primarily to support synapse function, and thus the realization that synapses are tripartite, has its origins at the NMJ ([@bib76]; [@bib14]; [@bib39]; [@bib99]; [@bib30]; [@bib9]; [@bib35]; [@bib51]; [@bib52]; [@bib62]; [@bib3]; [@bib4]; [@bib74]; [@bib97]). PSCs surround the NMJ where they are closely associated with its pre- and postsynaptic components ([@bib30]; [@bib43]; [@bib18]). In addition to providing trophic support for the NMJ ([@bib30]; [@bib43]; [@bib18]; [@bib71]), PSCs have been shown to guide motor axon innervation and synaptogenesis ([@bib71]; [@bib91]; [@bib44]; [@bib59]; [@bib5]), support compensatory axonal sprouting ([@bib3]; [@bib74]; [@bib88]; [@bib48]), participate in synaptic pruning ([@bib30]; [@bib46]; [@bib85]; [@bib17]), and detect and modulate cholinergic transmission ([@bib43]; [@bib36]; [@bib73]; [@bib77]; [@bib79]; [@bib80]).

While great progress has been made in understanding the cellular and physiological characteristics of PSCs, very little is known about the molecular composition of these cells ([@bib43]). This has been due to the absence of a cell-specific molecular marker with which PSCs can be identified, isolated, and genetically manipulated. This has hindered examinations of the processes of PSC development, differentiation and turnover. Additionally, isolation and targeting of PSCs for interrogation of molecular function in vivo and in vitro has not been possible. Therefore, the discovery of markers specific to PSCs is necessary to advance our understanding of PSCs, and synaptic glia in general, on multiple fronts.

A growing number of molecular markers that recognize subsets of glial cells throughout the nervous system have been identified ([@bib37]). Therefore, we explored the possibility that a unique combination of glial cell markers could be used to distinguish PSCs. We have found that PSCs can be identified by the combined expression of the calcium-binding protein B (S100β) ([@bib11]; [@bib63]) and neuron-glia antigen-2 (NG2) ([@bib89]; [@bib6]) genes. We utilized this unique molecular fingerprint to create a transgenic mouse that enables visualization and isolation of PSCs in a cell specific manner. This genetic model will help overcome obstacles to understanding the cellular and molecular rules that govern PSC function at NMJs during development, following injury, in old age, and in diseases, such as Amyotrophic Lateral Sclerosis (ALS).

Results {#s2}
=======

To identify unique markers for PSCs, we examined the expression of genes shown to be co-expressed with well-established markers of Schwann cells in a subset of glial cells in the central nervous system in PSCs. We focused on NG2 for the following reasons: 1) it has been found to be co-expressed with S100β, a classical marker of all Schwann cells, in a subset of glial cells in the developing brain ([@bib50]; [@bib32]; [@bib92]; [@bib55]; [@bib67]); 2) published data show that it is expressed in skeletal muscles and labels pericytes and neural progenitor cells ([@bib7]; [@bib8]). To determine if NG2 is expressed by PSCs, we examined whole-mounted extensor digitorum longus (EDL) muscles from NG2-dsRed mice ([@bib98]). We observed widespread distribution of NG2-dsRed postive cells in the EDL muscle, including a distinct subset of cells located specifically at the NMJ and with a similar morphology as PSCs ([Figure 1C](#fig1){ref-type="fig"}). To determine if NG2 is expressed in PSCs we generated a transgenic mouse line (referred herein as S100β-GFP;NG2-dsRed; [Figure 1A](#fig1){ref-type="fig"}) by crossing the NG2-dsRed line with the S100β-GFP mouse line in which the S100β promoter drives expression of GFP in all Schwann cells ([@bib99]). As expected, in the resulting S100β-GFP;NG2-dsRed double transgenic mouse line, dsRed labeled all NG2 positive cells (referred herein as NG2-dsRed^+^) and GFP labeled all Schwann cells (referred herein as S100β-GFP^+^) ([Figure 1B--C](#fig1){ref-type="fig"}) in skeletal muscles. However, we found a select subset of glia positive for both S100β-GFP and NG2-dsRed specifically located at the NMJ (yellow cells in [Figure 1D](#fig1){ref-type="fig"}). Based on the location and morphology of the cell body and its elaborations, we concluded that PSCs are the only cells expressing both S100β-GFP and NG2-dsRed in skeletal muscles.

![Co-expression of S100β and NG2 is unique to PSCs in the EDL muscle.\
(**A**) In order to selectively label PSCs, S100β-GFP and NG2-dsRed transgenic mice were crossed to create S100β-GFP;NG2-dsRed mice. (**B--D**) Representative images of GFP (**B**) and dsRed (**C**) fluorescence in the EDL of S100B-GFP;NG2-dsRed mice. S100β-GFP+ Schwann cells are visible along the motor axon while S100β-GFP+ PSCs are identified by their unique morphology and clustering pattern near the NMJ, visualized here using a fluourescent α-bungarotoxin conjugate (fBTX) to detect nAChRs (blue). Note that PSCs are the only cells expressing both GFP and dsRed (**D**). At non-synaptic sites, GFP-positive cells do not express dsRed (hollow arrow; **B', C', D'**) and dsRed-positive cells do not express GFP (filled arrow; **B', C', D'**). Scale bar = 50 μm (**D**), 25 μm (**D'**), and 10 μm (**D''**).](elife-56935-fig1){#fig1}

We next evaluated whether the S100β-GFP;NG2-dsRed mouse line serves as a reliable model to study PSCs and their roles at NMJs. In healthy young adult muscle, we observed the same number of PSCs at NMJs in the EDL muscle of S100β-GFP and S100β-GFP;NG2-dsRed mice ([Figure 2A--C](#fig2){ref-type="fig"}). The morphology of PSCs also appeared to be indistinguishable between the two transgenic lines. In addition, the morphology of NMJs, as assessed by fragmentation of nicotinic acetylcholine receptor (nAChR) clusters, is unchanged in S100β-GFP;NG2-dsRed mice compared to S100β-GFP and wild type mice ([Figure 2A,B,D](#fig2){ref-type="fig"}). Thus, the co-expression of S100β-GFP and NG2-dsRed does not appear to cause apparent deleterious changes on either PSCs or the postsynaptic region revealed by nAChRs. However, it remains possible that co-expression of these markers in PSCs may disrupt the presynapse and biophysical properties of the NMJ. If so, we hypothesize that such changes would be minor given that S100β-GFP;NG2-dsRed mice are outwardly indistinguishable when compared to S100β-GFP and wild type mice.

![The NG2-DsRed/S100β-GFP mouse line can be used to reliably identify PSCs in healthy and stressed NMJs.\
(**A--B**) Representative images of NMJs identified by fBTX labeled nAChRs from S100β-GFP (**A**) and S100β-GFP;NG2-dsRed (**B**) EDL. (**C--D**) The co-expression of GFP and dsRed has no discernible negative effects on NMJ fragmentation or PSC number in the EDL muscle of young adult mice. (**C**) The average number of PSCs per NMJ is unchanged between S100B-GFP mice and S100β-GFP;NG2-dsRed mice. (**D**) The average number of nAChR fragments per NMJ, as determined by analysis of continuity of fBTX labeled nAChRs, is unchanged between wild-type, S100B-GFP, and S100β-GFP;NG2-dsRed animals. (**E--H**) PSCs in stressed muscle co-express S100β-GFP and NG2-dsRed. Representative images of NMJs identified by fBTX labeled nAChRs in S100β-GFP;NG2-dsRed mice shows co-expression of S100β-GFP and NG2-dsRed by PSCs in healthy uninjured (**E**), at 4d (**F**), and 7d (**G**) post-fibular nerve crush, and in P120 SOD1G93A (**H**) EDL. At non-synaptic sites, GFP-positive cells do not express dsRed (hollow arrow; **E, F, G, H**) and dsRed-positive cells do not express GFP (filled arrow; **E, F, G, H**). Error bar = standard error of the mean. Scale bar = 10 μm (**A--B**), 50 μm (**E--H**), and 12.5 μm (E'-H' and E'=H').](elife-56935-fig2){#fig2}

We next assessed if S100β-GFP;NG2-dsRed mice could also be used to study PSCs at degenerating and regenerating NMJs. First, we examined expression of NG2-dsRed and S100β-GFP after crushing the fibular nerve ([@bib16]). In this injury model, motor axons completely retract within 1 day and return to reinnervate vacated postsynaptic sites by 7 days post-injury in young adult mice. Similar to healthy uninjured EDL muscles ([Figure 2E](#fig2){ref-type="fig"}), NG2-dsRed and S100β-GFP were found co-expressed exclusively in PSCs at 4d and 7d post-injury ([Figure 2F--G](#fig2){ref-type="fig"}). Second, we crossed the SOD1^G93A^ mouse line, ([@bib31]) a model of ALS shown to exhibit significant degeneration of NMJs ([@bib53]), with S100β-GFP;NG2-dsRed mice and examined the expression pattern of NG2-dsRed and S100β-GFP in the EDL during the symptomatic stage (P120). We again found NG2-dsRed and S100β-GFP co-expressed only in PSCs in the EDL of P120 SOD1^G93A^;S100β-GFP;NG2-dsRed mice ([Figure 2H](#fig2){ref-type="fig"}). Together, these data strongly indicate that this genetic labeling approach can be deployed to study the synaptic glia of the NMJ in a manner previously not possible in healthy and stressed NMJs.

To determine the relationship between NG2 expression and PSC differentiation, we analyzed NG2 expression in S100β-GFP^+^ Schwann cells during the course of NMJ development in the EDL muscle of S100β-GFP;NG2-dsRed mice ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We observed the presence of S100β-GFP^+^ cells at the NMJ as early as embryonic day 15 (E15) with 100% of NMJs having at least one S100β-GFP^+^ cell by post-natal day 9 ([Figure 3A,B](#fig3){ref-type="fig"}). During the embryonic developmental stages, we observed that NMJs are exclusively populated by S100β-GFP^+^ cells that do not express NG2-dsRed ([Figure 3C](#fig3){ref-type="fig"}). At post-natal day 0 (P0), however, we observed NG2-dsRed expression in a small subset of S100β-GFP^+^ cells ([Figure 3A,C](#fig3){ref-type="fig"}). Notably, the proportion of NMJs with S100β-GFP^+^;NG2-dsRed^+^ cells sharply increased between the ages of P0 and P9, coinciding with the period of NMJ maturation in mouse skeletal muscles ([Figure 3C](#fig3){ref-type="fig"}). By P21, when NMJ maturation in mice is near completion ([@bib81]), we observed S100β-GFP^+^;NG2-dsRed^+^ cells to be exclusively present at NMJs ([Figure 3C](#fig3){ref-type="fig"}). At this age, the number of S100β-GFP^+^;NG2-dsRed^+^ PSCs reached an average of 2.3 per NMJ and this remained unchanged in healthy young adult mice ([Figure 3A,D](#fig3){ref-type="fig"}). To confirm that dsRed expression from the NG2 promoter denotes the temporal and spatial transcriptional control of the NG2 gene in S100β-GFP;NG2-dsRed mice, we immunostained for NG2 protein. We found NG2 protein present at mature NMJs but not in NMJs of E18 mice with IHC ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Thus, the induced expression of NG2 during the course of NMJ development in Schwann cells located proximally to the NMJ provides further evidence that NG2 is a marker of mature, differentiated S100β^+^ PSCs. It is possible that PSCs upregulate NG2 during development in order to restrict motor axon growth at the NMJ ([@bib25]). Induced NG2 expression during NMJ development along with the constant presence of S100β-GFP^+^ cells (S100β-GFP^+^ or S100β-GFP^+^;NG2-dsRed^+^) and absence of single labeled NG2-dsRed+ cells at NMJs at every observed developmental time point ([Figure 3B,C](#fig3){ref-type="fig"}) strongly support previous studies indicating that PSCs originate from Schwann cells ([@bib46]).

![Analysis of NG2-dsRed distribution and PSC density during NMJ development in the EDL muscle.\
(**A**) Representative images of NMJs, identified by nAChR clusters with fBTX (blue), in developing (E15, P0, P6, P9, P21) and adult S100β-GFP (green);NG2-dsRed (red) transgenic EDL. (**B**) The number of NMJs populated by at least one S100β-GFP+ cell increases between the ages of E15 and P9, at which point all observed NMJs have at least one S100β-GFP+ cell. (**C**) Analysis of NMJs that contain at least one single labeled S100β-GFP+ cell (green bar), at least one double labeled S100β-GFP+;NG2-dsRed+ cell (yellow bar) or a combination of single labeled S100β-GFP+ cells and double labeled S100β-GFP+;NG2-dsRed+ cells (green/yellow bar) shows that developing NMJs are exclusively populated by S100β-GFP+ cells in the embryonic stages and are increasingly populated by S100β-GFP+;NG2-dsRed+ cells as the NMJ develops. (**D**) The average number of PSCs per NMJ increases during development. Error bar = standard error of the mean. Scale bar = 10 μm. \*=p \< 0.05,\*\*\*=P \< 0.001; \*\*\*\*=P \< 0.0001. Asterisks represent comparisons with P0 unless otherwise noted.](elife-56935-fig3){#fig3}

To gain insights into the rules that govern the distribution of PSCs at NMJs we compared PSC density in EDL, soleus, and diaphragm muscles to determine if PSC density is similar across muscles with varying NMJ sizes, fiber types and functional demands. Here, we observed similar PSC densities in each muscle type ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), suggesting that the number of PSCs directly correlates with the size of the NMJ and not the functional characteristics or fiber type composition of the muscles with which they are associated.

We next examined the spatial distribution of PSCs at the NMJ using the Nearest Neighbor (NN) analysis. This analysis measures the linear distance between neighboring cells in order to determine the regularity of spacing ([@bib93]; [@bib13]), quantified using the regularity index. In this analysis, randomly distributed groups of cells yield a nearest neighbor regularity index (NNRI) of 1.91 while those with nonrandom, regularly ordered distributions yield higher NNRI values ([@bib72]; [Figure 4A](#fig4){ref-type="fig"}). We found that the spacing of PSCs yielded high NNRI values and thus maintained ordered, non-random distributions at NMJs in the EDL muscle of adult mice. Moreover, this ordered distribution was maintained regardless of the overall number of PSCs at a given NMJ ([Figure 4B--D](#fig4){ref-type="fig"}). These observations are in accord with a published study indicating that PSCs occupy distinct territories at adult NMJs ([@bib10]). In addition, these data strongly suggest that presynaptic, postsynaptic, and/or PSC-PSC mechanisms of communication dictate the spatial distribution of PSCs.

![PSC distribution at the NMJ is non-random and ordered.\
(**A**) The nearest neighbor (NN) distance, or the distance between a PSC and the closest neighboring PSC, is represented by the red line. The distance represented by the purple line is not considered for NN analysis. The distribution of NN values (shown in panels B, C, and D) is used to determine the degree of order in PSC distribution, as represented by the nearest neighbor regularity index (NNRI). Distribution patterns with an NNRI value greater than 1.91 are considered to be non-random. (**B--D**) Nearest neighbor distributions of S100-GFP+;NG2-dsRed+ PSCs in adult (P60) EDL muscle show that PSC distributions have orderly patterns of distribution with NNRI \> 1.91 regardless of whether they are located at an NMJ with 2 PSCs (**B**), 3 PSCs (**C**), or 4 PSCs (**D**).](elife-56935-fig4){#fig4}

The ability to distinguish PSCs from all other Schwann cells makes it possible to identify genes that are either preferentially or specifically expressed in PSCs. We deployed fluorescence-activated cell sorting (FACS) to separately isolate double labeled S100β-GFP^+^;NG2-dsRed^+^ PSCs, single-labeled S100β-GFP^+^ Schwann cells, and single-labeled NG2-dsRed^+^ cells (including α-SMA pericytes and Tuj1^+^ precursor cells \[[@bib8]\]) from juvenile (P15-P22) S100β-GFP;NG2-dsRed transgenic mice. We then utilized RNA-Sequencing (RNA Seq) to compare the transcriptional profile of PSCs with the other two groups ([Figure 5A](#fig5){ref-type="fig"}). Light microscopy and expression analysis of GFP and dsRed using quantitative PCR (qPCR) confirmed that only cells of interest were sorted ([Figure 5A--B](#fig5){ref-type="fig"}). This analysis revealed a unique transcriptional profile for PSCs ([Figure 5C](#fig5){ref-type="fig"}). Notably, we found 567 genes enriched in PSCs that were not previously recognized to be associated with PSCs, glial cells or synapses ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) using Ingenuity Pathway Analysis (IPA). We also found a number of genes preferentially expressed by PSCs with known roles at synapses ([@bib56]; [@bib26]; [@bib69]; [@bib70]; [@bib84]; [@bib61]; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Providing additional insights about the function of PSCs, IPA revealed synaptogenesis, glutamate receptor, and axon guidance signaling as top canonical pathways under transcriptional regulation ([Figure 5D](#fig5){ref-type="fig"}).

![Molecular analysis of S100β-GFP+;NG2-dsRed+ PSCs, S100β-GFP+ Schwan cells, and NG2-dsRed+ cells following isolation with FACS.\
(**A**) Skeletal muscle from juvenile S100B-GFP;NG2-dsRed mice was dissociated and S100-GFP+;NG2-dsRed+ PSCs, S100β-GFP+ Schwan cells, and NG2-dsRed+ cells were sorted by FACS for RNA seq and qPCR. Representative fluorescence intensity gates for sorting of S100β-GFP+, NG2-dsRed+ and S100β-GFP+;NG2-dsRed+ cells are indicated in the scatter plot. GFP (y-axis) and dsRed (x-axis) fluorescence intensities were used to select gates for S100β-GFP+ cells (outlined in orange), NG2-dsRed+ cells (outlined in teal), and double labeled S100β-GFP+;NG2-dsRed+ cells (outlined in purple). Representative images of cells from sorted populations are shown. (**B**) GFP and dsRed qPCR was performed on FACS isolated cells to confirm specificity of sorting gates. (**C**) A heat map of RNA-seq results depicting genes with at least 5 counts and expression differences with a p-value of less than 0.01 between any 2 cell types reveals a distinct transcriptome in S100β-GFP+;NG2-dsRed+ PSCs versus S100β-GFP+ Schwann cells and NG2-dsRed+ cells. (**D**) Synaptogenesis and axon guidance signaling are among the most influential signaling pathways in PSCs according to Ingenuity Pathway Analysis of genes enriched in PSCs versus S100β-GFP+, and NG2-dsRed+ cells. (**E**) qPCR was performed on FACS isolated S100-GFP+;NG2-dsRed+ PSCs, S100β-GFP+ Schwan cells, and NG2-dsRed+ cells to verify mRNA levels of RNA seq identified PSC enriched genes. In each analysis, transcripts were not detected or detected at low levels in S100β-GFP+ Schwann cells and NG2-dsRed+ cells. Error bar = standard error of the mean. Scale bar = 10 µm.](elife-56935-fig5){#fig5}

We next cross-referenced our transcriptomic data with a list of genes compiled from published studies indicating enrichment or functional roles in PSCs ([@bib97]; [@bib74]; [@bib77]; [@bib79]; [@bib80]; [@bib27]; [@bib90]; [@bib54]; [@bib94]; [@bib75]; [@bib64]; [@bib60]; [@bib66]; [@bib22]; [@bib34]; [@bib33]; [@bib19]; [@bib57]; [@bib20]; [@bib24]; [@bib96]; [@bib65]; [@bib78]; [@bib29]; [@bib95]). This analysis identified 27 genes expressed in isolated S100β-GFP^+^;NG2-dsRed^+^ PSCs that were previously shown to be associated with PSCs ([Table 1](#table1){ref-type="table"}). These included genes involved in detection and modulation of synaptic activity such as adenosine ([@bib77]; [@bib80]), P2Y ([@bib77]; [@bib33]; [@bib19]), acetylcholine ([@bib79]; [@bib65]; [@bib95]) and glutamate receptors ([@bib66]), Butyrylcholinesterase (BChE) ([@bib65]), and L-type calcium channels ([@bib78]). Additionally, genes involved in NMJ development, synaptic pruning, and maintenance including agrin, 2\',3\'-cyclic nucleotide 3\' phosphodiesterase (CNP) ([@bib27]), Erb-b2 receptor tyrosine kinase 2 (Erbb2) ([@bib90]; [@bib54]; [@bib94]), Erbb3 ([@bib90]; [@bib75]) GRB2-associated protein 1 (Gab1) ([@bib60]), myelin-associated glycoprotein (MAG) ([@bib27]), and myelin protein zero (Mpz) ([@bib27]) were detected in PSCs.

###### Genes with functional roles in PSCs identified by RNA seq analysis of isolated PSCs.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene      Description                                      Proposed role                                            Read count   Log2 change vs\   Log2 change\    Reference
                                                                                                                                   NG2-dsRed+        vs S100β-GFP+   
  --------- ------------------------------------------------ -------------------------------------------------------- ------------ ----------------- --------------- --------------------------------
  Adora2a   Adenosine A2a receptor                           Detect/modulate synaptic activity                        8.1          −3.68             −2.67           ([@bib77]; [@bib80])

  Adora2b   Adenosine A2b receptor                           Detect/modulate synaptic activity                        9.2          −3.16             −4.55           ([@bib77]; [@bib80])

  Agrn      Agrin                                            AChR aggregation                                         2049.7       1.16              2.93            ([@bib27])

  Bche      Butyrylcholinesterase                            Modulate synaptic ACh levels                             7191.0       7.89              7.21            ([@bib90])

  Cacna1c   L type Calcium channel, alpha 1 c                Detect/modulate synaptic activity                        14.3         −4.92             −2.10           ([@bib54])

  Cacna1d   L type Calcium channel, alpha 1d                 Detect/modulate synaptic activity                        18.4         −0.42             −1.49           ([@bib54])

  Cd44      CD44 antigen                                     Mediates cell-cell interactions                          1249.2       0.75              −1.22           ([@bib94])

  Chrm1     Muscarinic acetylcholine receptor M1             Detect/modulate synaptic activity                        14.8         n.d.              0.89            ([@bib79]; [@bib75])

  Cnp       2\',3\'-cyclicnucleotide 3\' phosphodiesterase   Anchors axon terminal at NMJ                             2990.2       4.23              1.66            ([@bib64])

  Erbb2     Erb-b2 receptor tyrosine kinase 2                Synaptogenesis/maintenance                               228.9        0.84              1.37            ([@bib60]; [@bib66]; [@bib22])

  Erbb3     Erb-b2 receptor tyrosine kinase 3                Synaptogenesis/maintenance                               2471.3       7.05              4.46            ([@bib60]; [@bib34])

  GAb1      GRB2-associated protein 1                        Synaptic pruning                                         693.8        0.31              1.57            ([@bib33])

  Grm1      Glutamate receptor, metabotropic 1               Detect/modulate synaptic activity                        9.2          n.d.              0.80            ([@bib19])

  Grm5      Glutamate receptor, metabotropic 5               Detect/modulate synaptic activity                        38.0         n.d.              2.84            ([@bib19])

  LNX1      Ligand of numb-protein X 1                       Regulate NRG1 signaling                                  37.5         −2.29             −0.70           ([@bib62])

  MAG       Myelin-associated glycoprotein                   Synaptogenesis/maintenance                               136.0        3.12              −0.55           ([@bib64])

  Mpz       Myelin protein zero                              Synaptogenesis/maintenance                               4590.7       2.54              −0.79           ([@bib64])

  Nos2      Nitric oxide synthase 2, inducible               Synaptogenesis/modulate synaptic activity                13.4         −2.91             −1.28           ([@bib57])

  Nos3      Nitric oxide synthase 3, endothelial cell        Synaptogenesis/modulate synaptic activity                48.6         −2.69             −0.68           ([@bib57])

  P2ry1     Purinergic receptor P2Y1                         Detect/modulate synaptic activity, synapse elimination   144.4        0.52              2.21            ([@bib77]; [@bib20]; [@bib24])

  P2ry2     Purinergic receptor P2Y2                         Detect/modulate synaptic activity                        24.0         −1.55             −1.04           ([@bib77])

  P2ry10b   P2Y receptor family member P2Y10b                Detect/modulate synaptic activity                        10.0         −1.25             −3.14           ([@bib77])

  P2ry12    P2Y receptor family member P2Y12                 Detect/modulate synaptic activity                        273.5        n.d.              3.70            ([@bib77])

  P2ry14    P2Y receptor family member P2Y14                 Detect/modulate synaptic activity                        13.6         −3.49             −2.06           ([@bib77])

  S100b     S100 protein beta                                Intracellular signaling                                  1788.3       5.34              3.12            ([@bib74])

  Sema3a    Semaphorin 3a                                    Detect/modulate synaptic activity                        136.6        2.95              1.07            ([@bib96])

  Tgfb1     Transforming growth factor, beta 1               AChR aggregation                                         173.2        −1.08             −1.90           ([@bib65])
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We deployed quantitative PCR (qPCR) to validate preferential expression of select genes in PSCs. To do so, we obtained RNA from S100β-GFP^+^;NG2-dsRed^+^ PSCs, single-labeled S100β-GFP^+^ Schwann cells, and single-labeled NG2-dsRed^+^ cells isolated using FACS from juvenile S100β-GFP;NG2-dsRed transgenic mice. We examined eight genes identified by RNA seq as being highly enriched in PSCs. This included newly identified genes (Ajap1, Col20a1, FoxD3, Nrxn1, PDGFa, and Pdlim4) and genes previously shown to be enriched (BChE \[[@bib65]\] and NCAM1 \[[@bib15]\]) in PSCs ([Figure 5E](#fig5){ref-type="fig"}). Validating RNA-Seq findings, qPCR analysis showed that all eight genes are highly enriched in PSCs compared to all other cell types isolated via FACS ([Figure 5E](#fig5){ref-type="fig"}). Additionally, immunostaining showed that NG2, a novel PSC-enriched gene identified by RNA-Seq, is concentrated at the NMJ ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

Discussion {#s3}
==========

We have discovered a unique combination of molecular markers that allows us to specifically visualize, isolate, interrogate the transcriptome, and potentially alter the molecular composition of PSCs. We have shown that NG2 is specifically expressed by S100β-GFP^+^ PSCs but not myelinating S100β-GFP^+^ Schwann cells and thus the combined expression of S100β and NG2 is a unique molecular marker of PSCs in skeletal muscle. Providing further evidence that NG2 is a marker of differentiated PSCs, we have demonstrated that Schwann cells induce expression of NG2 shortly after they arrive at the NMJ during maturation of the synapse. However, the means by which the induced expression of NG2 is part of a program to establish and/or further specify PSC identity in Schwann cells at the NMJ, through activation of the NG2 promoter, remains to be determined.

We utilized FACS to isolate S100β-GFP^+^;NG2-dsRed^+^ PSCs from skeletal muscle to analyze the PSC transcriptome. To our knowledge this is the first time that the transcriptome of PSCs, or any other type of glial cell that associates exclusively with synapses, has been characterized. This analysis reveals expression of a number of genes that have been previously implicated in modulation of synaptic activity, synaptic pruning, and synaptic maintenance by PSCs. We identified a number of novel genes that are highly expressed in PSCs but not Schwann cells or NG2^+^ cells. These genes have the potential to assist PSC research by serving as molecular markers that can be utilized for PSC-specific genetic manipulations, PSC ablation, and isolation of PSCs for cell culture and molecular analysis. We verified a number of these with qPCR and IHC. This analysis, therefore, reveals a unique gene expression signature that distinguishes PSCs from all other Schwann cells.

While the role of the majority of genes found enriched in PSCs at the neuromuscular synapse remains to be determined, it is worth noting that many have been shown to play key roles in neuronal circuits in the central nervous system and in cell-cell communication. This is the case for NG2 which has been shown to terminate axonal growth in glial scars in the spinal cord ([@bib25]). Therefore, it is possible that NG2 is utilized by PSCs to tile, and thus occupy unique territories, and prevent motor axons from developing sprouts that extend beyond the postsynaptic partner. Supporting this possibility, we have found that the NG2 promoter is active in some PSCs at P0 ([Figure 3C](#fig3){ref-type="fig"}), a time when motor axon nerve endings at NMJs undergo rapid morphological changes ([@bib81]; [@bib82]). The progressive activation of the NG2 promoter in PSCs is complete by P9 ([Figure 3C](#fig3){ref-type="fig"}), which coincides with the elimination of extranumeral axons innervating the same postsynaptic site in mice ([@bib81]; [@bib82]). Therefore, PSCs may utilize NG2 to promote the maturation of the presynaptic region and thus the NMJ. Furthermore, PSCs may utilize NG2 to repel each other as they tile during development to occupy unique territories at the NMJ ([@bib10]).

With these tools, it is now possible to determine which cellular and molecular determinants are critical for PSC differentiation, maturation, and function at the NMJ. It will also allow us to ascertain the contribution of PSCs to NMJ repair following injury and NMJ degeneration during normal aging and the progression of neuromuscular diseases, such as Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). Our strategy of specifically labeling synaptic glia, using a combination of protein markers uniquely expressed in this cell type, may serve as a springboard for unprecedented approaches for studying not only PSC function at the NMJ, but also synapse-associated glia throughout the CNS. Indeed, we have observed subsets of astrocytes in the brain that co-express both S100β and NG2, as has been previously reported in the context of a lineage tracing analysis ([@bib21]). Future studies will determine the generality of our approach in discerning the functional roles of synaptic glia in the development, maintenance, and function of select synapses.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                     Designation                                        Source or\                                                      Identifiers                                                    Additional\
  (species) or\                                                                        reference                                                                                                                      information
  resource                                                                                                                                                                                                            
  --------------------------------- -------------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------- -------------------------------------------------
  Genetic reagent (*M. musculus*)   *S100b-GFP*                                        PMID:[15590915](https://www.ncbi.nlm.nih.gov/pubmed/15590915)   MGI:3588512                                                    Dr. Wesley Thompson (Texas A and M)

  Genetic reagent (*M. musculus*)   *NG2-dsRed*                                        PMID:[18045844](https://www.ncbi.nlm.nih.gov/pubmed/18045844)   MGI:3796063                                                    Dr. Akiko Nishiyama (University of Connecticut)

  Genetic reagent (*M. musculus*)   *SOD1^G93A^*                                       PMID:[8209258](https://www.ncbi.nlm.nih.gov/pubmed/8209258)     MGI:2183719                                                    Dr. Deng (Northwestern\
                                                                                                                                                                                                                      University)

  Antibody                          Guinea pig polyclonal anti-NG2                     PMID:[19058188](https://www.ncbi.nlm.nih.gov/pubmed/19058188)   Antibody Registry: AB_2572299                                  1:250

  Antibody                          Alexa Fluor-488 goat polycolonal anti guinea pig   Invitrogen                                                      RRID:[AB_2534117](https://scicrunch.org/resolver/AB_2534117)   1:1000

  Antibody                          Alexa Fluor-488 goat polyclonal anti rabbit        Invitrogen                                                      Catalog\# A-11008                                              1:1000

  Software, algorithm               Ingenuity Pathway Analysis                         Qiagen                                                          RRID:[SCR_008117](https://scicrunch.org/resolver/SCR_008117)   

  Software, algorithm               GraphPad Prism                                     GraphPad                                                        RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)   

  Software, algorithm               R                                                  The R Project for Statistical Computing                         RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)   

  Software, algorithm               ImageJ                                             ImageJ                                                          RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)   

  Software, algorithm               Bio-Rad CFX Manager                                Bio-Rad                                                         RRID:[SCR_017251](https://scicrunch.org/resolver/SCR_017251)   

  Commercial assay or kit           PicoPure RNA Isolation Kit                         ThermoFisher                                                    Catalog\#KIT0204                                               

  Commercial assay or kit           iScript cDNA synthesis kit                         Bio-Rad                                                         Catalog\#1708891                                               

  Commercial assay or kit           SsoAdvanced PreAmp Supermix                        Bio-Rad                                                         Cataolog\#1725160                                              

  Commercial assay or kit           iTAQ Univeral SYBR Green Supermix                  Bio-Rad                                                         Catalog\#1725121                                               

  Chemical compound, drug           Alexa Fluor-555 alpha- bungarotoxin                Invitrogen                                                      Catalog\#B35451                                                

  Chemical compound, drug           DAPI                                               ThermoFisher                                                    Catalog\#D1306                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

SOD1^G93A98 ^([@bib31]), S100β-GFP (B6;D2-Tg(S100b-EGFP)1Wjt/J) ([@bib99]) and NG2-dsRed mice (Tg(Cspg4-DsRed.T1)1Akik/J) ([@bib98]) were obtained from Jackson Labs (Bar Harbor, ME). S100β-GFP and NG2-dsRed mice were crossed to generate S100β-GFP;NG2-dsRed mice. Offspring were genotyped using Zeiss LSM900 to check for fluorescent labels. SOD1^G93A^ mice were crossed with S100β-GFP;NG2-dsRed mice to generate S100β-GFP;NG2-dsRed;SOD1^G93A^ mice. Postnatal mice older than 9 days of age were anesthetized and immediately perfused with 4% paraformaldehyde (PFA) overnight. Pups were anesthetized by isoflurane and euthanized by cervical dislocation prior to muscle dissociation. Adult mice were anesthetized using CO~2~ and then perfused transcardially with 10 ml of 0.1 [m]{.smallcaps} PBS, followed by 25 ml of ice‐cold 4% PFA in 0.1 [m]{.smallcaps} PBS (pH 7.4). All experiments were carried out under NIH guidelines and animal protocols approved by the Brown University and Virginia Tech Institutional Animal Care and Use Committee.

Fibular nerve crush {#s4-2}
-------------------

Adult S100β-GFP;NG2-dsRed mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) delivered intraperitoneally. The fibular nerve was crushed at its intersection with the lateral tendon of the gastrocnemius muscle using fine forceps, as described previously ([@bib16]). Mice were monitored for 2 hr following surgery and administered buprenorphine (0.05-.010 mg/kg) at 12 hr intervals during recovery.

Immunohistochemistry and NMJ visualization {#s4-3}
------------------------------------------

For NG2 immunohistochemistry (IHC), muscles were incubated in blocking buffer (5% lamb serum, 3% BSA, 0.5% Triton X-100 in PBS) at room temperature for 2 hr, incubated with anti-NG2 antibody (courtesy of Dr. Dwight Bergles) diluted at 1:250 in blocking buffer overnight at 4°C, washed 3 times with 0.1M PBS for 5 min. Muscles were then incubated with 1:1000 Alexa Fluor-488 conjugated anti-rabbit or guinea pig antibody (A-11008, Invitrogen, Carlsbad, CA) and 1:1000 Alexa Fluor-555 conjugated α-bungarotoxin (fBTX; Invitrogen, B35451) in blocking buffer for 2 hr at room temperature and washed 3 times with 0.1M PBS for 5 min. For all other NMJ visualization, muscles were incubated in Alexa Fluor-647 conjugated α-bungarotoxin (fBTX; Invitrogen, B35450) at 1:1000 and 4\',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI; D1306, ThermoFisher, Waltham, MA) at 1:1000 in 0.1M PBS at 4°C overnight. Muscles were then washed with 0.1M PBS 3 times for 5 min each. Muscles were whole mounted using Vectashield (H-1000, Vector Labs, Burlingame, CA) and 24 × 50--10.5 cover glass (ThermoFisher).

Confocal microscopy of PSCs and NMJs {#s4-4}
------------------------------------

All images were taken with a Zeiss LSM700, Zeiss LSM 710, or Zeiss LSM 900 confocal light microscope (Carl Zeiss, Jena, Germany) with a 20 × air objective (0.8 numerical aperture), 40 × oil immersion objective (1.3 numerical aperture), or 63 × oil immersion objective (1.4 numerical aperture) using the Zeiss Zen Black software. Optical slices within the z‐stack were taken at 1.00 μm or 2.00 μm intervals. High resolution images were acquired using the Zeiss LSM 900 with Airyscan under the 63 × oil immersion objective in super resolution mode. Optical slices within the z-stack were 0.13 μm with a frame size of 2210 × 2210 pixels. Images were collapsed into a two‐dimensional maximum intensity projection for analysis.

Image analysis {#s4-5}
--------------

### NMJ size {#s4-5-1}

To quantify the area of NMJs, the area of the region occupied by nicotinic acetylcholine receptors (nAChRs, labeled by fBTX, was measured using ImageJ software. At least 100 nAChRs were analyzed for number of fragments, individual nicotinic acetylcholine receptor (nAChR) clusters, from each muscle to represent an individual mouse. At least 3 animals per age group were analyzed to generate the represented data.

### Cells associated with NMJs {#s4-5-2}

Cell bodies were visualized via GFP and/or dsRed signal, and were confirmed as cell bodies by the presence of a DAPI+ nucleus. The area of each cell body was measured by tracing the outline of the entire cell body using the freehand tool in ImageJ. To quantify the number of cells associated with NMJs, the number of cell bodies directly adjacent to each NMJ was counted. Every cell that overlapped with or directly abutted the fBTX signal was considered adjacent to the NMJ. At least 3 animals per age group were analyzed to generate the represented data. Cells were examined in at least 100 NMJs from each muscle to represent an individual mouse.

### Spacing of PSCs at NMJs {#s4-5-3}

NMJs were identified via fBTX signal. PSCs were identified by the colocalization of GFP, dsRed, and DAPI signal in addition to their location at NMJs. The area of each PSC and NMJ was measured. The linear distance from the center of each PSC soma to the center of the nearest PSC soma at a single NMJ was measured. The distances were then separated into 5 μm bins and plotted in a histogram. All linear measurements were made using the line tool in the ImageJ software. At least 100 NMJs were analyzed from each muscle to represent an individual mouse.

Muscle dissociation and fluorescence activated cell sorting {#s4-6}
-----------------------------------------------------------

Diaphragm, pectoralis, forelimb and hindlimb muscles were collected from P15-P21 S100β-GFP;NG2-dsRed mice. After removal of connective tissue and fat, muscles were cut into 5 mm^2^ pieces with forceps and digested in 2 mg/mL collagenase II (Worthington Chemicals, Lakewood, NJ) for 1 hr at 37°C. Muscles were further dissociated by mechanical trituration in Dulbecco's modified eagle medium (Life Technologies, Carlsbad, CA) containing 10% horse serum (Life Technologies) and passed through a 40 µm filter to generate a single cell suspension. Excess debris was removed from the suspension by centrifugation in 4% BSA followed by a second centrifugation in 40% Optiprep solution (Sigma-Aldrich, St. Louis, MO) from which the interphase was collected. Cells were diluted in FACS buffer containing 1 mM EDTA, 25 mM Hepes, 1% heat inactivated fetal bovine serum (Life Technologies), in Ca^2+^/Mg^2+^ free 1X Dulbecco's phosphate buffered saline (Life Technologies). FACS was performed with a Sony SH800 Cell Sorter (Sony Biotechnology, San Jose, CA). Representative fluorescence intensity gates for sorting of S100-GFP^+^, NG2-dsRed^+^ and S100-GFP^+^;NG2-dsRed^+^ cells are provided in [Figure 5](#fig5){ref-type="fig"}. Purity of the sorted cell population was confirmed by visual inspection of sorted cells using an epifluorescence microscope and with dsRed and GFP qPCR ([Figure 5A,B](#fig5){ref-type="fig"}). A single mouse was used for each replicate and an average of 7500 cells per replicate were collected for each cell group.

RNA-seq and qPCR {#s4-7}
----------------

RNA was isolated from S100β-GFP^+^, NG2-dsRed^+^, or S100β-GFP^+^/NG2-dsRed^+^ cells following FACS with the PicoPure RNA Isolation Kit (ThermoFisher). The maximum number of cells that could be collected by FACS following dissociation of muscles collected from one mouse was used as a single replicate. On average, a single replicate consisted of 7,500 cells. RNA seq was performed by Genewiz on 12 replicates per cell type. Following sequencing, data were trimmed for both adaptor and quality using a combination of ea-utils and Btrim ([@bib2]; [@bib45]). Sequencing reads were aligned to the genome using HiSat2 ([@bib42]) and counted via HTSeq ([@bib1]). QC summary statistics were examined to identify any problematic samples (e.g. total read counts, quality and base composition profiles (+/- trimming), raw fastq formatted data files, aligned files (bam and text file containing sample alignment statistics), and count files (HTSeq text files). Following successful alignment, mRNA differential expression were determined using contrasts of and tested for significance using the Benjamini-Hochberg corrected Wald Test in the R-package DESeq2 ([@bib47]). Failed samples were identified by visual inspection of pairs plots and removed from further analysis resulting in the following number of replicates for each cell type: NG2-dsRed^+^, 10; S100β-GFP^+^, 7; NG2-dsRed^+^;S100β-GFP^+^, 9. Functional and pathway analysis was performed using Ingenuity Pathway Analysis (QIAGEN Inc, <https://www.qiagenbio-informatics.com/products/ingenuity-pathway-analysis>). Confirmation of expression of genes identified by RNA-seq was performed on 6 additional replicates of each cell type using quantitative reverse transcriptase PCR (qPCR). Reverse transcription was performed with iScript (Bio-Rad, Hercules, CA) and was followed by a preamplification PCR step with SsoAdvanced PreAmp Supermix (Bio-Rad) prior to qPCR using iTAQ SYBR Green and a CFX Connect Real Time PCR System (Bio-Rad). Relative expression was normalized to 18S using the 2^-ΔΔCT^ method. The primers used for both preamplification and qPCR are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}.

Statistics {#s4-8}
----------

An unpaired t-test or one-way ANOVA with Bonferroni post hoc analysis were used for statistical evaluation. Data are expressed as the mean ± standard error of the mean, and p\<0.05 was considered statistically significant. The number of replicates is as follows: RNA seq, 7--10; qPCR, 6; comparisons between EDL, soleus, and diaphragm, 1; comparison between SOD1^G93A^ and healthy adult muscle, 1; all other analyses, 3. Statistical analyses were performed using GraphPad Prism8 and R. Data values and p-values are reported within the text.

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R01AG055545 to Gregorio Valdez.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R56AG051501 to Gregorio Valdez.

-   http://dx.doi.org/10.13039/100000002National Institutes of Health R21NS106313 to Gregorio Valdez.

We thank members of the Valdez laboratory for providing helpful comments throughout the course of this project.

Additional information {#s5}
======================

No competing interests declared.

Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing.

Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing.

Data curation, Formal analysis, Writing - original draft, Writing - review and editing.

Formal analysis, Writing - review and editing.

Resources, Writing - review and editing.

Formal analysis, Methodology, Writing - original draft, Writing - review and editing.

Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Writing - review and editing.

Animal experimentation: All experiments were carried out under NIH guidelines and animal protocols approved by the Brown University (IACUC\# 19-05-0013) and Virginia Tech (IACUC\# 18-148 and 18-176) Institutional Animal Care and Use Committee.

Additional files {#s6}
================

###### Genes with highly enriched expression in perisynaptic Schwann cells.

###### Primers used for cDNA preamplification and qPCR.

Data availability {#s7}
=================
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Perisynaptic Schwann cells (PSCs) at the neuromuscular junction (NMJ) play essential roles in synaptic function, formation, maintenance, and repair. However, the molecular characteristics specific to PSCs are largely unknown. In this manuscript, Castro et al., have adopted a novel approach of combining S100B and NG2 labels to reveal a specific probe for PSCs and identify several associated novel genes. Their new discoveries advance molecular understanding of synapse-glia interactions at the NMJ in health and disease, and provide a foundation for further exploration.

**Decision letter after peer review:**

Thank you for submitting your article \"Specific labeling reveals unique cellular and molecular features of synaptic Schwann cells\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Gary Westbrook as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Chien-Ping Ko (Reviewer \#2). The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in *eLife* but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data. Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in *eLife*, either of which would be linked to the original paper.

Summary:

The manuscript by Castro et al. describes the use of combined S100b and NG2 to identify perisynaptic (terminal) Schwann cells at the neuromuscular junction. The role of PSCs in the development, function, degeneration and regeneration of the NMJ is well established, but their careful study has been limited by a lack of molecular markers. This study convincingly demonstrates that combined expression of S100b (labeling all Schwann cells) and NG2, labeling only relatively mature terminal Schwann cells (as well as other cell types in muscle) can be combined to study, and more importantly isolate, PSCs. Some data presented largely reproduce previous findings regarding PSCs, but this information serves to validate the use of S100b/NG2 to identify this population. Given the long-standing interest in identifying specific markers of PSCs to allow their isolation and manipulation, these findings are important for the field. However, a few items would improve the manuscript and data presentation. as guided by the Essential revisions section below.

Essential revisions:

1\) Address each of the key comments (below) in the revised paper, especially regarding the potential limitations and uncertainties of the new marker, as raised by both reviewers.

2\) Transcriptional Profiling of PSCs

-- More could be done to validate the top DE genes using RNA scope and in situ hybridization. That is relatively straightforward technically if this is possible during covid19 period. For example, the authors provide only one IHC for validation beyond the qPCR and it is not clear why an adherens junction (Ajap1) would show diffuse cytoplasmic localization, so more will need to be done to validate this antibody and show that immunoreactivity is indeed AJAP1 (in addition to validating other DE genes). The authors are referred to the above paragraph regarding *eLife* policy during COVID-19 for our expectations.

-- Are there other NG2^+^ cells in muscle and if so, this needs to be considered in the interpretation of the current RNA-seq data from this population?

-- The presentation of the RNA-seq data could be formatted to be a little more useful to help rank candidates of interest, including read count and fold change (similar format to Table 1). See comments reviewer 2.

Revisions expected in follow-up work:

-- Additional validation and spatial mapping of more DE expressed genes (sm FISH with combinations of markers).

Reviewer \#1:

Comments have been incorporated into the editorial comments above.

Reviewer \#2:

Perisynaptic Schwann cells (PSCs) at the neuromuscular junction (NMJ) play essential roles in synaptic function, formation, maintenance, and repair. However, the molecular characteristics specific to PSCs are largely unknown. In this manuscript, Castro et al. have adopted a novel approach of combining S100B and NG2 labels to reveal a specific probe for PSCs and identify several associated novel genes. The manuscript is well-written and comprehensive. Their findings are truly exciting, compelling, and immensely significant, as the field desperately needs specific probes for PSCs. Their new discoveries would advance molecular understanding of synapse-glia interactions at the NMJ in health and disease.

1\) Introduction, last paragraph and Results, first paragraph. The authors may like to comment on whether they are the first group to show NG2 at PSCs and/or how they came up with the idea of combining both S100B and NG2 for their approach to identify PSCs. It would also be useful to comment/speculate the potential function of NG2 and other genes such as Ajap1 in PSCs.

2\) Results, first paragraph, Figure 1F. The authors use the AChR fragmentation index to assess if NMJ deterioration occurs in their transgenic mouse line. It would be more sensitive and informative by also labeling the presynaptic nerve terminals to check if there is denervation. In addition, it is desirable to examine the quantal contents to confirm if indeed there are no functional deficits at the NMJ in their transgenic mice.

3\) It is unclear about the statement, \"we failed to find.... throughout the course of embryonic and postnatal development.\" But NG2 is expressed at least partially starting from P0 (Figure 2C). The authors may also like to comment/speculate on the reason/significance for NG2 expression only for mature differentiated PSCs.

4\) The authors used FACS to isolate S100B-GFP^+^;NG2-dsRed^+^ PSCs from skeletal muscles to analyze the PSC transcriptome. However, it appears that NG2 expresses only in PSCs after birth and in mature PSCs (Figure 2C, Figure 2---figure supplement 1). It is also not known whether denervation after nerve injury and subsequent repair would alter the expression of NG2. If NG2 is downregulated or absent in denervated PSCs, their new probes for PSCs and associated genes might not be able to address the role of PSCs after nerve injury. It would be desirable to perform a relatively straightforward experiment by simply examining NG2 staining after nerve injury. This additional experiment would broaden the applications of using their transgenic line to address a key role of PSCs in synaptic repair in future studies. Otherwise, their approaches would be somewhat limited to studying only the mature PSCs in intact muscles.

Reviewer \#3:

The paper by Castro et al. describes the use of combined S100b and NG2 to identify perisynaptic (terminal) Schwann cells at the neuromuscular junction. Besides the identification of this marker combination, the most significant results presented are the transcriptional profile of these cells isolated by flow cytometry from muscle. Given the long-standing interest in identifying specific markers of PSCs to allow their isolation and manipulation, these findings are important for the field. The image quality in the paper is excellent, and the quantification and statistics are rigorous and convincing. A few items would further improve the manuscript and data presentation.

The authors should comment on what the other NG2^+^ cells in muscle may be (recognizing there may be multiple cell types). This would help in future studies attempting to use a similar intersectional approach to study PSCs and also in the interpretation of the current RNA-seq data from this population (indeed, the -seq may help with the identification of these cell types).

The list of genes in Supplementary file 1 that also show enrichment in the S100b^+^/NG2^+^ cells versus either single marker is a potentially very useful resource for the field. As such, it should include some additional information to help rank candidates of interest, including read count and fold change (similar format to Table 1, without references and proposed functions).

There is a lot of future potential to be based on this work (response to denervation/axotomy, status and gene expression changes in disease, genetic ablation, etc.). Addition of such studies would strengthen this paper, but also require significant time and effort and exactly which of these studies would be most important and most informative is hard to predict. Therefore, the intrinsic value of publishing the identification of these markers and the list of PSC-enriched genes is noted as it will allow the field to subsequently pursue these additional experiments.

10.7554/eLife.56935.sa2

Author response

> Essential revisions:
>
> 1\) Address each of the key comments (below) in the revised paper, especially regarding the potential limitations and uncertainties of the new marker, as raised by both reviewers.
>
> 2\) Transcriptional Profiling of PSCs
>
> -- More could be done to validate the top DE genes using RNA scope and in situ hybridization. That is relatively straightforward technically if this is possible during covid19 period. For example, the authors provide only one IHC for validation beyond the qPCR and it is not clear why an adherens junction (Ajap1) would show diffuse cytoplasmic localization, so more will need to be done to validate this antibody and show that immunoreactivity is indeed AJAP1 (in addition to validating other DE genes). The authors are referred to the above paragraph regarding eLife policy during COVID-19 for our expectations.

We thank the reviewer for this comment, and agree that further validation of differentially expressed genes would strengthen this dataset. However, our lab does not currently possess the proper tools and equipment to perform in situ hybridization and/or RNA scope. Obtaining and setting up this equipment would take considerable time, and would require the purchase of new materials and equipment. It is unlikely that this will be possible in the immediate future due to COVID-19 restrictions, which for example continues to keeps us away from our lab and will make it difficult to purchase additional items not deemed necessary. Please do note that we do intend to obtain the equipment necessary to begin performing these and other important techniques for assessing PSCs in our lab once we resume "normal" research activities and as funds become available. However, we hope that our current validation using immunohistochemistry and qPCR will be sufficient at this time. Given that it will not be possible to validate our Ajap1 antibody with Ajap1 knockout tissue, we have removed the Ajap1 IHC results from the manuscript (changes made to Figure 5 and Results, last paragraph).

> -- Are there other NG2^+^ cells in muscle and if so, this needs to be considered in the interpretation of the current RNA-seq data from this population?

The reviewer has brought attention to an area of the manuscript that is currently lacking in sufficient detail. We have updated the text to include a better account of the types of cells that express NG2 in muscles based on published work by Birbrair A, et al., 2013a, b (changes made to Results, first and eighth paragraphs). We have also updated the text to reflect the fact that the collection of NG2-dsRed^+^ cells from muscles for RNA-seq represents a heterogeneous population of cell-types.

> -- The presentation of the RNA-seq data could be formatted to be a little more useful to help rank candidates of interest, including read count and fold change (similar format to Table 1). See comments reviewer 2.

We have modified the presentation of our RNA-seq data in Supplementary file 1 to include read count and fold change. Our entire RNA-seq data-set has been deposited in the NCBI-GEO database as well, so all of this information will be readily available to the reader.

> Revisions expected in follow-up work:
>
> -- Additional validation and spatial mapping of more DE expressed genes (sm FISH with combinations of markers).
>
> Reviewer \#1:
>
> Comments have been incorporated into the editorial comments above.
>
> Reviewer \#2:
>
> \[...\] 1) Introduction, last paragraph and Results, first paragraph. The authors may like to comment on whether they are the first group to show NG2 at PSCs and/or how they came up with the idea of combining both S100B and NG2 for their approach to identify PSCs. It would also be useful to comment/speculate the potential function of NG2 and other genes such as Ajap1 in PSCs.

We thank the reviewer for pointing out this important omission. This manuscript concerns the discovery of new molecular markers, and we failed to explain in sufficient detail how that discovery was made. We have updated the text to rectify this mistake (changes made to Results, first paragraph). We have also expanded the text to include a more detailed discussion of the possible roles of NG2 in NMJ development (changes made to Discussion, third paragraph).

> 2\) Results, first paragraph, Figure 1F. The authors use the AChR fragmentation index to assess if NMJ deterioration occurs in their transgenic mouse line. It would be more sensitive and informative by also labeling the presynaptic nerve terminals to check if there is denervation. In addition, it is desirable to examine the quantal contents to confirm if indeed there are no functional deficits at the NMJ in their transgenic mice.

We agree with the reviewer that analysis of presynaptic nerve terminals and quantal content would contribute to our analysis here, and we cannot discount the possibility that there are currently unidentified negative consequences of the co-expression of GFP and dsRed in PSCs. Unfortunately, performing these additional analyses would take a great deal of time and resources, and would be difficult to complete in a timely manner as long as COVID-19 restrictions persist. In this revision, we have added that we see no discernible differences between general features of S100B-GFP^+^ animals and NG2dsRed^+^/S100B-GFP^+^ animals, such as overall health or basic motor capacity (changes made to Results, second paragraph). We have also added a sentence that discusses this particular limitation of the study. Additionally, we see no changes in PSC number (Figure 1E) between NG2-dsRed^+^ and NG2-dsRed^-^ animals.

> 3\) It is unclear about the statement, \"we failed to find.... throughout the course of embryonic and postnatal development.\" But NG2 is expressed at least partially starting from P0 (Figure 2C). The authors may also like to comment/speculate on the reason/significance for NG2 expression only for mature differentiated PSCs.

We agree with the reviewer that we were unclear in the quoted section of the text. We have updated the text to clarify when NG2 appears in PSCs. Additionally, we included text describing the possible function of NG2 at the NMJ (changes made to Results, fourth paragraph).

> 4\) The authors used FACS to isolate S100B-GFP^+^;NG2-dsRed^+^ PSCs from skeletal muscles to analyze the PSC transcriptome. However, it appears that NG2 expresses only in PSCs after birth and in mature PSCs (Figure 2C, Figure 2---figure supplement 1). It is also not known whether denervation after nerve injury and subsequent repair would alter the expression of NG2. If NG2 is downregulated or absent in denervated PSCs, their new probes for PSCs and associated genes might not be able to address the role of PSCs after nerve injury. It would be desirable to perform a relatively straightforward experiment by simply examining NG2 staining after nerve injury. This additional experiment would broaden the applications of using their transgenic line to address a key role of PSCs in synaptic repair in future studies. Otherwise, their approaches would be somewhat limited to studying only the mature PSCs in intact muscles.

We agree with the reviewer and have added additional data and information that demonstrate the wide-spread utility of these markers to study PSCs at NMJs under various stressors (Figure 2E-H). This includes data showing that PSCs continue to be the only cells expressing both GFP and dsRed (proxies for S100B and NG2) after crushing innervating motor axons and during the symptomatic stage of ALS in a mouse model of the disease characterized by significant destruction of NMJs (changes made to Results, third paragraph). These data strongly indicate that these markers will be sufficient to study PSCs in diseases, injury and potentially during aging.

> Reviewer \#3:
>
> The paper by Castro et al. describes the use of combined S100b and NG2 to identify perisynaptic (terminal) Schwann cells at the neuromuscular junction. Besides the identification of this marker combination, the most significant results presented are the transcriptional profile of these cells isolated by flow cytometry from muscle. Given the long-standing interest in identifying specific markers of PSCs to allow their isolation and manipulation, these findings are important for the field. The image quality in the paper is excellent, and the quantification and statistics are rigorous and convincing. A few items would further improve the manuscript and data presentation.
>
> The authors should comment on what the other NG2^+^ cells in muscle may be (recognizing there may be multiple cell types). This would help in future studies attempting to use a similar intersectional approach to study PSCs and also in the interpretation of the current RNA-seq data from this population (indeed, the RNA-seq may help with the identification of these cell types).

We agree, see response to Essential revisions.

> The list of genes in Supplementary file 1 that also show enrichment in the S100b^+^/NG2^+^ cells versus either single marker is a potentially very useful resource for the field. As such, it should include some additional information to help rank candidates of interest, including read count and fold change (similar format to Table 1, without references and proposed functions).

We agree, see response to Essential revisions.

> There is a lot of future potential to be based on this work (response to denervation/axotomy, status and gene expression changes in disease, genetic ablation, etc.). Addition of such studies would strengthen this paper, but also require significant time and effort and exactly which of these studies would be most important and most informative is hard to predict. Therefore, the intrinsic value of publishing the identification of these markers and the list of PSC-enriched genes is noted as it will allow the field to subsequently pursue these additional experiments.
